IMMUNOMODULATION IN GYNECOLOGY. OPINION OF AN IMMUNOLOGIST AND AN OBSTETRICIAN-GYNECOLOGIST

Mardanov Gayrat Abdisalomovich

IMMUNOMODULATION IN GYNECOLOGY. OPINION OF AN IMMUNOLOGIST AND AN OBSTETRICIAN-GYNECOLOGIST

Mardanov Gayrat Abdisalomovich

Termez branch of Tashkent medical academy

##semicolon## chronic, pathogen, immune system, reproductive, carcinoprevention

सार

The currently available information on the epidemiological features and chronic clinical course of diseases caused by sexually transmitted pathogens is the reason for the search for drugs and methods that increase the effectiveness of their therapy [1]. A very serious problem for clinicians is the polyresistance of pathogens to antiviral, antimicrobial and antifungal drugs, the high frequency of infection of various population groups with herpes viruses, human papillomaviruses, their negative impact on the immune system and factors of colonization resistance of the reproductive tract

##submission.citations##

Khryanin A.A., Tapilskaya N.I., Knorring G.Yu. Modern concepts of human papillomavirus infection: epidemiology and management of patients with anogenital warts. Clinical dermatology and venereology. 2020; 19(5): 719–728.

Magalhães G.M., Vieira E.C., Garcia L.C. et al. Update on human papilloma virus: epidemiology, pathogenesis, and clinical spectrum. an. Bras. Dermatol. 2021; 96(1): 1–16.

Rosales R., Rosales C. Immune therapy for human papillomaviruses-related cancers. World J. Clin. oncol. 2014; 5(5): 1002–1019.

Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. C.A. Cancer J Clin. 2021; 71(3): 209–249.

Abu-Lubad M.A., Jarajreh D.A., Helaly G.F. et al. Human papillomavirus as an independent risk factor of invasive cervical and endometrial carcinomas in Jordan. J. Infect. public health. 2020; 13(4): 613–618.

Boda D., Docea A.O., Calina D. et al. Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues (review). Int. J. Oncol. 2018; 52(3): 637–655.

Yang X., Lu L. Expression of HPV-16 E6 protein and p53 inactivation increases the uterine cervical cancer invasion. drug. Res. (Stuttg.). 2015; 65:70–73.

Amador-Molina A., Hernández-Valencia J.F., Lamoyi E. et al. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses. 2013; 5(11): 2624–2642.

Perlamutrov Yu.N., Soloviev A.M., Ataullakhanov P.P. et al. The use of an activator of antiviral immunity in the complex therapy of patients with recurrent genital warts. Issues of gynecology, obstetrics and perinatology. 2005; 4(3): 65–68.

Barros M.R. Jr., de Melo C.M.L., Barros M.L.C.M.G.R. et al. Activities of stromal and immune cells in HPV-related cancers. J. Exp. Clin. Cancer Res. 2018; 37(1):137.

Serov V.N., Dubnitskaya L.V., Tyutyunnik V.L. Inflammatory diseases of the pelvic organs: diagnostic criteria and principles of treatment. Russian medical journal. 2011; 19(1): 46–50.

Gizinger O.A., Radzinsky V.E. Human papillomavirus: pathogenesis and correction of immune disorders. Doctor. RU. 2021; 20(6): 80–86.

Ghochikyan A. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. J. Transl. Med. 2014; 12:322.

Pichugin A.V. Immunomodulator Immunomax activates dendritic cells. Immunology. 2015; 36(4): 200–205.

Donnikov A.E., Markelov M.I., Pestrikova T.Yu. Analysis of the prevalence and viral load of various types of human papillomavirus in the regions of the Russian Federation. Obstetrics and gynecology. 2019; 4:39–47.

Rakhmatulina M.R., Tarasenko E.N. The frequency of detection of fungi of the genus Candida in patients with urogenital candidiasis and analysis of their antimycotic resistance over a ten-year period (2010-2020). Obstetrics and gynecology. 2020; 7:159–165.

Bukatina T.M. Sodium-glucose cotransporter 2 inhibitors: risk of ketoacidosis and candidiasis. Safety and risk of pharmacotherapy. 2016; 2:33–39.

Bibicheva T.V., Lukashov M.I. Clinical efficacy of monotherapy of recurrent herpetic infection of the genital organs of the genitourinary tract with the immunomodulator Gepon. Kursk scientific and practical bulletin "Man and his health". 2009; 3:47–54.

Uchaikin V.F. Gepon is a domestic immunomodulator with anti-inflammatory and antiviral activity for children and adults. A guide for doctors. M., 2003.

Ataullakhanov R.I., Holmes R.D., Narovlyansky A.N. Changes in the transcription of cytokine genes in transplanted human cells under the influence of the immunomodulator Gepon. Allergy, asthma and clinical immunology. 2002; 9:17–22.

Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015; 122(6): 785–794.

Tishchenko A.L. A new approach to the treatment of recurrent urogenital candidiasis. Gynecology. 2001; 3(6):210–212.

Instructions for the medical use of the drug Immunomax, lyophilizate for the preparation of a solution for intramuscular injection. R N001919/02 dated 10/17/2011.

Ataullakhanov R.I., Pichugin A.V., Shishkova N.M. et al. Cellular mechanisms of the immunomodulatory action of the drug Immunomax. Immunology. 2005; 26(2): 111–120.